Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Biotechnology

Healthcare
$1.56 +3.16%

+$0.05 today

Market cap
$66.94M
Beta
1.91
P/E (TTM)
-0.8
EPS (TTM)
-$2.00
52W Low $1.15High $3.56

Volume 0.61M

Average 0.60M

ACRV Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 38.72M shares rose 1.0% year over year, behind the +2.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +20.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.0% toward the trailing-twelve-month pace of +2.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
38.72M+0.6% QoQ
Last fiscal yearDec 2025
38.51M+0.6% YoY
LTMMar 2026
38.56M+2.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.0%——
1 year+0.6%——
3-year CAGR+20.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
38.51M USD
Year-over-year change
+0.6%
4-year CAGR
+31.4%

Weighted Avg Shares vs competitors

How ACRV compares with its peers on the latest reported figures

  • ACRV's LTM Mar 2026 weighted avg shares of 38.56M shares is the 9th highest of the 10 companies compared; the peer median is 95.83M shares.
  • Its year-over-year change of +2.3% is the lowest of 10, against a peer median of +55.6%.
  • Over three fiscal years its annual growth of +20.7% compares with a peer median of +21.3%.
ACRV Competitors Peer median
Weighted Avg Shares for ACRV and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.05M +14.5%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1278.7%+372.5%
ATYRaTyr Pharma, Inc.LTM Mar 202695.83M +20.8%+48.5%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding ACRV) 95.83M+55.6%+21.3%

Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00536K1.01M1.36M
Gross Profit00(536K)(1.01M)(1.36M)
Gross Margin—————
Research & Development13.72M23.95M45.49M63.99M59.99M
Selling, General & Admin2.47M8.71M21.21M25.21M24.12M
Operating Expenses16.18M32.66M66.7M88.19M82.76M
Depreciation & Amortization37K364K536K1.01M1.36M
EBITDA(16.21M)(30.8M)(59.85M)(79.55M)(76.55M)
EBITDA Margin—————
Operating Income(16.18M)(32.66M)(67.24M)(89.2M)(84.11M)
Operating Margin—————
Interest Income007.04M9.2M6.48M
Interest Expense00000
Other Income / Expenses(59K)1.49M6.85M8.64M6.21M
Income Before Tax(16.24M)(31.17M)(60.39M)(80.56M)(77.91M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(16.24M)(31.17M)(60.39M)(80.56M)(77.91M)
Net Margin—————
EPS (Basic)(1.26)(1.42)(2.74)(2.10)(2.02)
EPS (Diluted)(1.26)(1.42)(2.74)(2.10)(2.02)
Weighted Avg Shares12.91M21.92M22.08M38.3M38.51M
Weighted Avg Shares (Diluted)12.91M21.92M22.08M38.3M38.51M

Acrivon Therapeutics, Inc. Common Stock

NASDAQ:ACRV

Intrinsic Alpha fair value

Locked

Current Price

$1.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.